HVLP – Antivirotikum pro systémové použití – HCV – Elbasvir – Grazoprevir II.
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| 10117668 | 11/25/2019 | Merck Sharp & Dohme s.r.o. | 35,334,200.00 | 32,122,000.00 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| 509_Písemná zpráva.pdf | Písemná zpráva zadavatele | 12/09/2019, 01:18 PM | Dokument není zavirovaný | ||
| 509_Písemná zpráva.pdf | Písemná zpráva zadavatele | 02/28/2023, 03:15 PM | Dokument není zavirovaný |
List of Participants
| Show detail | |||||||
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme s.r.o. | Praha 5 | 35,333,760.00 | 32,121,600.00 | CZK |
Price Actually Paid in Each Year of Performance
| 10117668 | 2023 | 1,985,236.57 | 1,804,760.52 |
| 10117668 | 2022 | 4,540,395.29 | 4,127,632.08 |
| 10117668 | 2021 | 5,300,064.00 | 4,818,240.00 |
| 10117668 | 2020 | 3,180,038.00 | 2,890,944.00 |